This article was sponsored by ACCELERATE.

After its approval by the US Food and Drug Administration (FDA) in 2017, the 

 system has been helping to revolutionize the treatment of infectious diseases in the United States.

The system, which is fully automated, allows physicians to identify pathogens in 90 minutes and then provides information on treatment options within a few more hours—including an ability to test the susceptibility of the said pathogen to multiple antibiotics. The system even provides a scoring scale to determine the best option for treatment.

All this is compared to the normal 2-day identification time and 3-day antibiotic testing time frames of conventional methods of testing. These require using a patient’s blood sample to grow bacteria and then identify the infection via biochemicals. Only after that process can antibiotics be tested.

Accelerate Pheno does this by recording video of the pathogen in questions’ growth, then utilizing computer algorithms to compare the growth patterns to its archive of patterns, something never before done in clinical diagnostics.

“We are one of the first in the world introducing this technology,” Eric R. Rosenbaum, MD, MPH, FCAP, an attending and clinical pathologist at the University of Arkansas for Medical Sciences (UAMS) and Arkansas Children's Hospital, as well as the medical director of the University’s Clinical Microbiology Laboratory, said in a 

. “The way it works is nothing short of revolutionary — part of a wider renaissance in clinical microbiology we are experiencing. But more importantly for our clinicians and patients, what it gives them is time.”

that even in the first few weeks of having access to the technology, the lab has seen great results. The device, he said, offers more than just new technology—it offers time to patients, which is invaluable in so many ways, especially in the infectious disease space. It could be the difference between exposing a patient to a therapy that could unnecessarily increase the risk of adverse events (AEs), as well as the use of higher cost medicines or an increased stay.

“It has already allowed us to reduce a patient’s exposure to zosyn and vancomycin, and de-escalate them onto ceftriaxone, which could be the difference maker in reducing their potential for AEs such as acute kidney injury," Rosenbaum said. "That decreases the length of stay—which starts to add up for the patient cost. If we can get rid of the bacterium, and do it without risk of other AEs, that’s a huge win for us.”

“Every one of these where we can make an intervention sooner is a win. I am really happy with what this brings to our immune suppressed patients and our healthy patients. I just wish more of them knew we had this technology," he added.

In addition to UAMS, the Peninsula Regional Medical Center (PRMC) in Maryland has also adopted the use of the instrument—and has also noted its successes. PRMC utilized the system before making it available to patients on December 4, 2017, in order to test its success and accuracy.

Beth Prouse, MS, MLS, ASCP, a clinical microbiologist at PRMC, noted in a 

 that while the PRMC was impressed with the speed of the tool, its precision was more pressing, and was an essential reason for its adoption.

“It is a process that used to take days, and now, in about 7½ hours, we can talk to clinicians about which antibiotic would be most effective for their patient, and tailor their antibiotic therapy,” Prouse said. “The sooner we get the patient on the right antibiotic, the shorter their illness.”

It has made a difference in the lab, as well, Rosenbaum said. The Accelerate Pheno cuts down on benchwork, and cuts down on susceptibility setups and interpretation and reading the next day, which results in savings. "It is also reducing the time we spend setting up with traditional methods—about 30 mins per specimen. That’s 30 mins that can be used to do something else," he said.

The product has the ability to serve a population in need of quicker response and treatment times. The Centers for Disease Control and Prevention has released data noting that at least 23,000 people die each year from antibiotic-resistant infections.

“This feature is new and unique,” Rosenbaum noted. “It means getting patients on the most appropriate antibiotic days faster, off more-expensive broad-spectrum antibiotics and on the road to recovery.”

Men Who Have Sex with Men Receive Less HIV Education

Immunometabolic Agitations Raises Risk of CVD in Patients with HIV

Synthetic Peptide Could Limit Drug-Resistant Bacteria Function

Articles

The Accelerate PhenoTM system allows for pathogen identification in only 90 minutes, and is revolutionizing infectious disease diagnostics.

Accelerate Pheno System Speeds Up Antibiotic Susceptibility Diagnostics

This article was sponsored by AstraZeneca

The cardiovascular healthcare environment today is significantly different than it was 20 years ago; new drugs are available for cardiovascular conditions, and the internet has brought a wealth of healthcare education to patients’ fingertips.

Despite these advances, cardiovascular disease (CVD) remains the number 1 cause of death in the world. When we look specifically at acute coronary syndrome (ACS), an umbrella term encompassing aspects of CVD, such as myocardial infarction (MI) and unstable angina, we see that 790000 people have a heart attack in the US each year (580000 new attacks and 210000 recurrent attacks), leading to 114000 deaths.

For patients who have suffered a heart attack, various lifestyle changes can help them manage the risk of another thrombotic cardiovascular (CV) event, including engaging in regular physical activity, managing stress, and following a healthy diet. In addition, guideline driven secondary prevention strategies have been shown to reduce the risk another thrombotic CV event.

 Dual antiplatelet therapy (DAPT), which consists of aspirin plus a second oral antiplatelet (OAP), usually a P2Y

 inhibitor, may play a major role in the treatment paradigm in patients with ACS and has been shown to significantly reduce the risk of subsequent thrombotic cardiovascular events.

However, treatment adherence to post-MI guideline recommendations is poor in patients with ACS. A study by Faridi and colleagues showed that rates of adherence to secondary prevention therapies were no higher than 69% after 3 months and 64% after 1 year.

A study, which analyzed 15 studies from 7 countries, determined the primary variables correlated with nonadherence to P2Y

 inhibitors. These variables included factors related to demographic (eg, age, ethnicity, education), treatment (eg, experiencing side effects), healthcare system process (eg, a lack of discharge information), clinical (eg, pre-existing comorbidities), opportunity (eg, cost), and psychosocial (eg, patient related factors like forgetfulness or feeling treatment is not necessary).

Given the high rates of nonadherence that occur very early after discharge from the hospital, several approaches have been suggested to help improve the chances that patients with ACS will continue taking their medications as prescribed by their doctor. For one, clinicians can educate their patients about developing habits and routines for taking their medications as soon as they are discharged from the hospital, helping to establish a longer-term pattern of adherence.

 As part of this “early intervention” approach, clinicians should consider assessing a patient’s medication use at their first post-MI outpatient visit to encourage continued adherence. If a follow-up cannot be scheduled this early after discharge, clinicians may want to consider other approaches, such as telehealth technologies.

Another approach for helping patients reduce nonadherence is a 90-day medication supply. One study has shown that 90-day prescriptions can increase adherence over 30-day prescriptions.

 This study, conducted by Taitel and colleagues, was a retrospective observational study of California Medicaid claims for over 50,000 patients receiving medication for common chronic illness. Overall, the 90-day medication supply increased adherence by 23% over the 30-day supply, with only nominal drug wastage. Even after subtracting drug wastage compared with the 30-day supply, the 90-day drug supply produced an average drug savings per person per year in the range of $7.00-$26.00 due to the benefit of reduced fees and volume discounts.

Given the potential adherence advantages of a 90-day medication supply, AstraZeneca has introduced the BRILINTA $18 Card that allows eligible commercially insured patients to pay as little as $18 for up to a 90-day supply on each refill, as long as their doctor prescribes BRILINTA. BRILINTA

 (ticagrelor) tablets, which has no generic equivalent, has 98% unrestricted access across commercial insurances. It’s also important to note that for Medicare Part D patients, BRILINTA will cost less than $1.50 per day based on an average co-pay of less than $45 per month. It is crucial to make this empowered patient demographic aware of all potential treatment options and not let cost keep physicians from prescribing the right medication for the right patient.

 is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

 Additionally, according to the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy (DAPT), BRILINTA is preferred over clopidogrel in ACS (Class IIa: LOE B-R).

 BRILINTA is also recommended for use as DAPT for at least 12 months in patients with ACS and as a treatment option in patients with ACS who undergo stent implantation or are managed with medical therapy alone (Class I: LOE B-R).

IMPORTANT SAFETY INFORMATION FOR BRILINTA

WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding

Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage

Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery 

If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events

B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided

BRILINTA is contraindicated in patients with a history of intracranial hemorrhage or active pathological bleeding such as peptic ulcer or intracranial hemorrhage. BRILINTA is also contraindicated in patients with hypersensitivity (eg, angioedema) to ticagrelor or any component of the product

Dyspnea was reported in about 14% of patients treated with BRILINTA, more frequently than in patients treated with control agents. Dyspnea resulting from BRILINTA is often self-limiting

Discontinuation of BRILINTA will increase the risk of MI, stroke, and death. When possible, interrupt therapy with BRILINTA for 5 days prior to surgery that has a major risk of bleeding. If BRILINTA must be temporarily discontinued, restart as soon as possible

Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the post-marketing setting. PLATO and PEGASUS excluded patients at increased risk of bradyarrhythmias not protected by a pacemaker, and they may be at increased risk of developing bradyarrhythmias with ticagrelor

Avoid use of BRILINTA in patients with severe hepatic impairment. Severe hepatic impairment is likely to increase serum concentration of ticagrelor and there are no studies of BRILINTA in these patients

The most common adverse reactions associated with the use of BRILINTA included bleeding and dyspnea: In PLATO, for BRILINTA vs clopidogrel, non-CABG PLATO-defined major bleeding (3.9% vs 3.3%) and dyspnea (14% vs 8%); in PEGASUS, BRILINTA vs aspirin alone, TIMI Total Major bleeding (1.7% vs 0.8%) and dyspnea (14% vs 6%)

Avoid use with strong CYP3A inhibitors and strong CYP3A inducers. BRILINTA is metabolized by CYP3A4/5. Strong inhibitors substantially increase ticagrelor exposure and so increase the risk of adverse events. Strong inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor

Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse events

Monitor digoxin levels with initiation of, or change in, BRILINTA therapy

BRILINTA (ticagrelor) tablets is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.

BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.

Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association. 

Faridi KF, Peterson ED, McCoy LA, et al. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. 

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 

Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes.

Johnston N, Weinman J, Ashworth L, et al. Systematic reviews: causes of non-adherence to P2Y

 inhibitors in acute coronary syndromes in response to intervention. 

Molloy GJ, Messerli-Bürgy N, Hutton G, et al. Intentional and unintentional non-adherence to medications following an acute coronary syndrome: A longitudinal study. 

Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. 

Taitel M, Fensterheim L, Kirkham H, et al. Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid. 

Brilinta [package insert]. Wilmington, DE: AstraZeneca; 2017.

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 

One study has shown that 90-day prescriptions can increase adherence over 30-day prescriptions.

Sponsored

Accelerate Pheno System Speeds Up Antibiotic Susceptibility Diagnostics

Adherence to ACS Medications: A Path Forward for Improved Patient Care